Title: Synergic effects of anticancer peptide CIGB-552 and Cisplatin in lung cancer models
Authors: Yolanda Gomez Rodriguez1, Brizaida Oliva Arguelles2*, Mario Riera-Romo3*, Jorge Fernandez-De-Cossio4, Freya Milagro Freyre Almeida5, Yaima Chacon Quintero6, Amalia Vazquez Arteaga5, Tania Cardenas Borrego6, Rocio Garateix Suarez6, Enma Brown Richards7, Dagmara Pichardo Diaz7, Lizet Aldana Velazco7, Hilda Elisa Garay8, Julio Fernandez Masso2, Maribel Guerra Vallespi2.
1 Pavillon de Recherche Appliquée sur le Cancer (PRAC), Université de Sherbrooke, Québec, Canada.
2 Pharmaceutical Department, Laboratory of Cancer Biology, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
3 Radiology Department, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
4 Department of Bioinformatics, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
5 Analytical laboratory, Chemical-Physical Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
6 Vaccine Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
7 Animal Facility Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
8 Peptide Synthesis Division, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
*Correspondence to:Brizaida Oliva Arguelles, Laboratory of Cancer Biology, Center for Genetic Engineering and Biotechnology (CIGB), Cubanacan, P.O. Box 6162, 10600 Havana, Cuba.Email:brizaida.oliva@gmail.com, brizaida.oliva@cigb.edu.cu
*Mario Riera-Romo, Leiden University Medical Center (LUMC), P.O. Box 9600, 2300 RC Leiden, The Netherlands, Email:rieraromo@gmail.com, M.Riera_Romo@lumc.nl